ICICI Pru Nifty Pharma Index Fund
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
Growthvine rating: 4/5 — ranked #26 of 245 in category.
Fund basics
| Category | Equity: Index |
|---|
| NAV | ₹19.89 (as of 2026-10-01) |
|---|
| AUM | ₹157 Cr |
|---|
| Expense ratio | 0.89% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ashwini Jemin Bharucha |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.92 |
|---|
| Standard deviation | 15.94% |
|---|
| Max drawdown | −16.78% |
|---|
| Alpha | -1.03 |
|---|
| Beta | 0.94 |
|---|
Market cap allocation
| Large cap | 47.8% |
|---|
| Mid cap | 45.0% |
|---|
| Small cap | 7.1% |
|---|
Concentration
| Top 5 holdings | 55.2% |
|---|
| Top 10 holdings | 78.8% |
|---|
| Total holdings | 20 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 20.8%
- Divis Laboratories Ltd. — 11.9%
- Cipla Ltd. — 7.8%
- Laurus Labs Limited — 7.4%
- Torrent Pharmaceuticals Ltd. — 7.3%
- Dr. Reddys Laboratories Ltd. — 6.9%
- Lupin Ltd — 5.3%
- Aurobindo Pharma Ltd. — 4.7%
- Glenmark Pharmaceuticals ltd — 3.7%
- Alkem Laboratories Limited — 3.1%
Top sectors
- Pharma & Biotech — 99.9%
- Cash — 0.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 15.5% | — | — |
| 2025 | −3.2% | — | — |
| 2024 | 38.0% | — | — |
| 2023 | 31.9% | — | — |